Please login to the form below

Not currently logged in
Email:
Password:

Mylan hires Jacek Glinka as European head

He will join the firm from Poland’s Polpharma

Mylan Jacek GlinkaUS pharma company Mylan has named Jacek Glinka as president of its European business.

Glinka will join Mylan in December when he steps down from his role as CEO of Poland's Polpharma, which he headed up from 2003 to 2006 and then again from 2009 to the present.

During this time, he helped expand Polpharma from a small local biopharma to one that now stretches across Central and Eastern Europe and Asia. As a result of the expansion, including takeovers of firms in Poland and Kazakhstan, revenues doubled between 2011 and 2013 to reach more than $1bn.

In his role at Mylan, Glinka will oversee the company's growth plans in Europe and will report to chief operating officer Hal Korman.

“We believe Jacek's strong leadership, strategic thinking and operational discipline will build on the solid foundation and leadership team we already have in place, and maximise the many opportunities we see ahead for our European business,” said Mylan's CEO Heather Bresch.

Glinka added that he had been following Mylan for some time and he was confident that company could become a serious competitor in Europe.

“I look forward to leveraging my expertise, particularly in the exciting Central and Eastern European markets, to further expand Mylan's footprint,” he said.

21st October 2013

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anatomy Health

We are a health information design consultancy focused on developing simple, accessible and inclusive patient communications. From evaluating existing patient...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics